

Index

a

acetylacetone, 38, 139
 2-acetylcyclohexanone, 44, 63
 4-acetyl-4'-(5-hexenyl-oxy)azobenzene, 259, 260
 acid-catalyzed tautomerization, 290
 β -alanine, 136
 alicyclic β -diketones, 17, 18
 alicyclic lactams, 14, 15
 allylic tautomerism, 21
 amide tautomerism, 107, 108
 amino acids, 135, 136
 2-aminoazoles, 26, 27
 4-amino-*N*-(4,6-dimethyl-2-pyrimidinyl)-benzenesulfonamide, 312
 aminophenols, 137, 138
 6-amino-2-(phenylsulfonylimino)-1,2-dihydropyridine, 311
 annular tautomerism, 296, 297
 anthraquinone Schiff base, 235
 aromaticity, 2
 asymmetric heteroaromatic amidines, 100, 101
 aza-acenes, 220
 7-azaindole, 135
 azapentalenes, 25–29
 azobenzenes
 – chromophore applications, 255
 – dyes, 234
 – photochromism, 254–256
 azonaphthols, 286
 azophenols
 – fast-responding artificial muscles, 266–268
 – optical oscillators, 262–265
 – photochromes, 256
 – thermal isomerization kinetics

– isotropic solvents, 256–258
 – liquid-crystalline and glassy media, 259–262

b

B97D/aug-cc-pVQZ single point energy calculations, 115
 barbituric acid (H3BA), 317–319
 benzazolo-oxazolidine derivatives, 175
 biological activity, 4, 5
 butyrolactam, 134

c

chromogenic azobenzocrown ethers, 281
 cis-amides, 12, 13
 citrinin, 52
 conformational effects, 30, 32
 constitutional isomers, 113, 119
 controlled tautomerism
 – cavities, 279, 282
 – electron acceptor substituent, manipulation of, 275–277
 – metal-free naphthalocyanine, 274
 – proton cranes, 283–285
 – protonation/deprotonation and complexation, 274
 – tweezers, 278
 coumarin Schiff base, 235
 crystal engineering, aim of, 297
 C-type tautomerism, 95
 cyclohexane-1,2-dione, 23
 cyclohexane-1,3-dione, 139
 cytosine, 132

d

1-deazapurine, 305–307
 dehydrogenated tetraphenylporphyrin molecule, 155

density functional theory (DFT) calculations
 – coupling constants, 66–68
 – energies, 62
 – isotope effects, 68–70
 – NMR chemical shifts, 63–65
 – nuclear shielding surface, 62, 63
 – vibrational frequencies, 70
 depolarization ratio (DR), 181
 4-(diazenyl)phenol, 280
 diazophenylcalix[4]arene, 281
N,N-dihydrooctaazatetracenes, 223
 dihydro-5,7,12,14-tetraazapentacene, 220
 dihydrodiazatetracene, 221
 β -diketones, 37, 43, 44, 279
 3,6-dimethyl-1,8-dihydroxy-
 2-acetylnaphthalene, 53
 3,6-dimethyl-1,8-dihydroxy-
 2,7-diacetylnaphthalene, 53
 dimethylindanone, 85
N,N'-diphenyl-6-aminofulvene-1-aldimine,
 334
N,N'-diphenyl-1-amino-3-imino-propen,
 339
 double proton transfers, 339
 double proton-relay, 121, 122, 129, 134
 dynamic NMR (DNMR) studies, 6

e

EFISHG, *see* electric field-induced second
 harmonic generation
 electric field-induced second harmonic
 generation (EFISHG), 179
 electrofuge, 329
 energy-dispersive X-ray diffraction, 57
 enol imine – enaminone tautomerism, 140
 enol–keto tautomerism, 277
 enolimine/ketoenamine prototropic
 tautomerism
 – benzoannelation, 230
 – *bis*-imines, 231
 – intramolecular hydrogen bonds, 231
 – ionochromic sensing
 – – anthraquinone Schiff base, 235
 – – aza-15-crown-5 containing
 4-(phenyldiazenyl)naphthalen-1-ol,
 241
 – – azobenzene dyes, 234
 – – bidentate crown containing Schiff bases,
 241
 – – chelation-enhanced fluorescence
 quenching, 236
 – – CHEQ/ESIPT effects, 236
 – – coumarin Schiff base, 235

– – coumarin-based imine, 236
 – – Crown ether containing Schiff base, 243
 – – dansyl cadaverine derivative, 238
 – – fluorogenic chemosensor, 240
 – – gossypol Schiff bases, 241
 – – “naked-eye” chemosensor effect, 242
 – – naphthalene Schiff base, 234
 – – PVC matrix inserted Schiff base, 238
 – – rhodamine-based chemodosimeter, 239,
 240
 – – urea- and thiourea containing Schiff base,
 236
 – *o*-hydroxybenzo[*b*]furan carbaldehydes,
 232
 – salicylidene imines, 232
 – Schiff bases, 233
 – solid phase study, 229
 – technical applications, 229
 equilibrium constant, 118, 119
N-(5-ethyl-1,3,4-thiadiazol-2-yl)-
 p-toluenesulfonylamide, 59
 exchange-correlation (XC) functionals, 183
 excited state intramolecular proton transfer
 (ESIPT) process, 3, 283
 excited state tautomerism
 – porphycene, 56, 57
 – porphyrine, 56, 58
 explicit solvent methods, 116

f

FEP/MC simulations, 117, 126, 129, 131, 134,
 136, 137, 139–142
 five-membered ring acylamidines, 31
 five-membered ring oxoheterocycles, 16
 functional tautomerism, 296, 297

g

gas phase kinetic aspects, 5, 6
 gas phase tautomerism, 60
 gas phase thermodynamic aspects, 2–4

h

2,4,6-heptanetrione, 296
 4-(5-hexenyloxy)azobenzene, 256
 4-(5-hexenyloxy)-4'-hydroxyazobenzene,
 259, 260
 heteroaromatic amidines, 109, 110
 Hine's Principle of Least Motion, 12
 histamine, 131, 141
 histidine, 64, 131, 345
 host-guest molecular switches, 273
 HRS, *see* hyper-Rayleigh scattering
 human carbonic anhydrase II, 344, 346

hydrogen bonding, 330–332
 4-hydroxyquinoline, 289
 o-hydroxy acylaromatics, 49
 4-hydroxyazobenzene, 256
 o-hydroxyazo-hydrazo tautomerism, 41
 10-hydroxybenzo[*h*]quinoline, 289, 290
 5-hydroxyisoxazole, 128, 130
cis-2-hydroxy-5-methyl-azobenzene, 258
 7-hydroxy-8-(*N*-morpholinomethyl)quinoline, 283
 hydroxy-oxo tautomerism, 130, 132
 2-(4'-hydroxyphenylazo)benzoic acid, 288
 3-hydroxy pyrazole, 128
 3-hydroxy-4-pyridincarboxaldehyde and 4-*R*-anilines, 277
 4-hydroxyquinoline, 288
 7-hydroxyquinoline, 283
 o-hydroxy Schiff bases, 45, 55, 56, 69
 hydroxy-substituted azobenzenes, *see* azophenols
 hyper-Rayleigh scattering (HRS), 176, 179

i

IEF-PCM geometry optimizations, 136, 137, 139–141
 imine–enamine system
 – carbon substituted, 105–107
 – nitrogen substituted, 102–104
 in-solution tautomeric equilibria
 – acetylacetone, 139
 – amino acids, 135, 136
 – aminophenols, 137, 138
 – 7-azaindole, 135
 – butyrolactam, 134
 – cytosine, 132
 – drug partitioning, 125–127
 – enol imine – enamionone tautomerism, 140
 – equilibrium constant, 118, 119
 – extended bifunctional muscarinic agonists, 124, 125
 – five-member heterocycles, 129, 130
 – guanine...cytosine pair, 129, 133
 – histamine, 131
 – histidine, 131
 – 5-hydroxyisoxazole, 128, 130
 – 3-hydroxy pyrazole, 128
 – malondialdehyde, 138
 – nitrosoalkane–oxime tautomerism, 140
 – 2-OH pyridine, 131
 – 4-OH pyridine, 131
 – phenol–quinone tautomerism, 140
 – relative solvation free energy, 116, 117
 – SBD process, 123
 – succinimide, 134

– sugars, 140
 – thymine, 133
 – uracil, 133
 – warfarin, 123
 inelastic electron tunneling process, 147, 151
 Infra red (IR) spectroscopy, 55, 71
 intermolecular tautomerizations
 – without requiring reorganization of environment
 – – pre-equilibria absence, 338–340, 342
 intramolecular hydrogen-bonds (IMHB), 2, 3, 231, 278
 intramolecular tautomerizations
 – without requiring reorganization of environment, 334, 335, 338

k

keto–enol tautomerism, 120, 138, 139, 285
 keto–enol tautomerization, 290
 ketone tautomerism, 107, 108

l

light-triggered smart materials, 253, 268
 linear reduced fused oligo-1,4-pyrazines, *see* pyrazinacenes
 liquid single crystal elastomers (LSEs), 266–268
 liquid-crystalline elastomers (LCEs), 266
 liquid state tautomerism, 36
 lone pair effects, 29
 low-temperature STM, 155,
 – *see also* scanning tunneling microscopy

m

maleic hydrazide, 18, 20
 malondialdehyde, 138, 139
 malonic acid enolization, 58
 mandelic acid (MA), 205–211, 213
 Mannich bases, 358
 matrix isolation spectroscopy, 56
 mechanically interlocked molecular switches, 273
 mechanochemical grinding reactions, 307
 metastable tautomers, 304
 o-methylacetophenone, 81, 82
 o-methylbenzophenone, 78
 N-methyl piperazine, 141
 microwave (MW) spectroscopy, 2
 molecular devices, 273
 molecular switches, 273
 molecular-scale devices, 147
 monoprotic tautomerism, 221
 multicomponent X . ap polymorphs, 309

n

- naphthalocyanine derivatives, 152
- near-edge X-ray absorption fine structure spectroscopy (NEXAFS), 56
- NH tautomerism, 221
- N-(4-nitrobenzyl)-OxC, 218, 219
- nitrosoalkane-oxime tautomerism, 140
- NLO switching, *see* nonlinear optical (NLO) switches
- NMR method, 2, 5
- nonlinear optical (NLO) switches
 - anils
 - – solid state photochromism, 194–196
 - – solvent effects, 191–193
 - – structure-property relationships, 187, 190, 191
 - EFISHG, 179
 - first hyperpolarizability, 175, 179
 - HRS, 179, 181
 - molecular compounds and solids, 178, 179
 - molecular quadratic hyperpolarizabilities, 181, 182, 184, 185
 - octupolar systems, 175
 - second-order responses, 175, 185, 186
- N-salicylideneaniline derivatives, 177
- N-type tautomerism, 96

o

- 2-OH pyridine, 131
- 4-OH pyridine, 131
- omeprazole, 316
- organic molecular switches, 175
- oxadiazoles, 25
- oxocorroligen (OxC), 203, 204, 212, 214–218
- oxoporphyrinogen (OxP), 203–213

p

- Pauling's valence bond order concept, 331
- pharmaceutical tautomeric solids, 295, 296
- phenol–quinone tautomerism, 140
- 1-phenylazo-2-naphthol, 59
- 4-(phenyldiazenyl)naphthalen-1-ol, 285
- photoactive yellow protein (PYP), 351
- photochromic molecules, 254
- photochromic systems, 273
- photodeformable materials, 254
- photoinduced enolizations, 77
- photoswitchable materials, 254
- phthalocyanine, 336
- phthalocyanine derivatives, 153
- piroxicam, 314–316
- PLP, *see* pyridoxal 5'-phosphate (PLP)

- polarizable continuum model (PCM), 296, 305
- polymorphism, 4
- porphycene, 57, 59, 61, 62
- porphyrine, 58
- potential energy surface (PES), 114
- 1-propionyl-2-hydroxynaphthalene, 42
- protic solvents, 122
- protic tautomerism, 203
- proton sponges, 347, 351
- proton transfer, 332
- protonation influenced tautomerism, 278
- 1,2-prototropic shift, 120
- prototropic tautomerism, 1, 113, 209, 296
- prototropic tautomerization, 120
- prototropy, 329
- pyrazinacenes, 203–205, 219–224
- 2*H*-pyrazinacenes, 219
- pyrazoles, 297
- pyrazolines, 297
- pyridoxal 5'-phosphate (PLP), 360, 361, 363, 364
- 5-{4-[(2-pyridylideneamino)sulfonyl]-phenyldiazenyl}salicylic acid, 311

q

- quantum mechanical calculations, 114

r

- relative solvation free energy, 116, 117
- ring-chain tautomerism, 329

s

- salicylidene based Schiff base, 308
- SBD process, *see* structure based drug design (SBD) process
- scanning tunneling microscopy, 147
 - configuration schematics, 148
 - inelastic electron tunneling process, 151
 - local electronic states, 149, 150
 - porphycene molecule tautomerization
 - – *cis* – *cis* tautomerization, 159–161, 167, 168
 - – adsorption structure of, 156–158
 - – copper adatom creation, 167
 - – dI/dV spectra, 164, 165
 - – fractional population, 162, 166
 - – inner cavity geometry of, 155, 156
 - – molecular assemblies, 170, 171
 - – tautomerization yields *vs.* voltage, 163
 - – thermally induced *cis* – *cis* tautomerization, 158, 159
 - – total energy calculations, 169, 170

- – tunneling current vs. tautomerization rates, 163, 164
 - single-molecule tautomerization
 - – dehydrogenated tetraphenylporphyrin molecule, 154, 155
 - – naphthalocyanine derivatives, 152
 - – phthalocyanine derivatives, 153
 - – tetraphenylporphyrin (TPP) molecule, 153, 154
 - theoretical model, 149
 - working principle, 148
 - Schiff bases, 40, 297, 359, 360
 - single molecule tautomerism, 59–62
 - 6-membered ring lactams, 14
 - slow thermally-isomerizing azo derivatives, 256
 - solid phase kinetic aspects, 5, 6
 - solid phase thermodynamic aspects, 3–5
 - solid state proton transfer (SSPT), 5
 - solid state tautomerism, 300, 302
 - NMR isotope effects, 58, 59
 - X-ray diffraction, 59, 60
 - solution phase kinetic aspects, 5, 6
 - solution phase thermodynamic aspects, 2–5
 - solvatomers, 333
 - STM, *see* scanning tunneling microscopy
 - structure based drug design (SBD) process, 123
 - succinimide, 134
 - sugars, chain-ring transformation for, 140
 - sulfamethazine, 312, 313
 - sulfasalazine, 311, 312
 - sulfonamides, 310
 - supramolecular synthons, 298, 299
 - symmetrical guanidines, 96–98, 100
- t**
- tautomeric switching system, 274
 - tautomerizations requiring reorganization of environment, 346
 - charged molecules and hydrogen bonded clusters
 - – homoconjugated carboxylic acid carboxylates, 354, 356
 - – phenol- and carboxylate moieties, 351, 353, 354
 - – proton sponges, 347, 349, 350
 - – neutral heterocyclic acid-base complexes
 - – acid-pyridine type complexes, 356–358
 - – Mannich bases, 358
 - PLP dependent enzyme reactions, 360, 362–364
 - – Schiff bases, 359, 360
 - meso*-5,10,15,20-*tetrakis*(3,5-di-*t*-butyl-4-hydroxyphenyl)porphyrin, 203
 - meso*-5,10,15,20-*tetrakis*(3,5-di-*t*-butyl-4-oxocyclohexadien-2,5-ylidenyl)porphyrinogen, 203
 - 8-(1,4,7,10-tetraoxa-13-azacyclopentadec-13-ylmethyl)quinolin-7-ol, 284
 - tetraphenylporphyrin (TPP) molecule, 153, 154
 - tetrapyrrole macrocycles, 203
 - theoretical chemistry, 7
 - theoretical equilibrium studies, 115
 - 2-thiobarbituric acid (H3TBA), 320, 321, 323
 - β -thioxoketones, 36, 37
 - thymine, 133
 - time-dependent density functional theory (TDDFT) method, 183
 - trans*-to-*cis* isomerization, 255
 - triage system, 11
 - 1,2,3-triazole, 39
 - triazolones, 24, 25
 - 1,2,3-tricarbonyl-2-arylhydrazones, 290
 - 1,1,1-(2,4,6-trihydroxybenzene-1,3,5-triyl)(2,4,6-trihydroxy-1,3,5-triacetylbenzene), 62
 - meso*-5,10,15-*tris*(3,5-di-*t*-butyl-4-oxocyclohexadien-2,5-ylidenyl)corrologen, 203
 - Tsuchida–Yamabe (TY) mechanism, 121, 122
- u**
- uracil, 133
 - UV/VIS spectroscopy, 2, 53, 54
- v**
- vinylous heteroaromatic amidines, 110
- w**
- warfarin tautomers, 124
 - Wentzel – Kramers – Brillouin (WKB) approximation, 149
 - Winstein – Holness equation, 6
- x**
- X-ray crystallography, 3

